Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
  • Peer groups
    • HR Peer Group
    • Recruitment Peer Group
    • Marketing Peer Group
    • PA Peer Group
More
    • Contact us
    • Join the network
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job
    • Peer groups
      • HR Peer Group
      • Recruitment Peer Group
      • Marketing Peer Group
      • PA Peer Group

    Breadcrumb

    1. Home
    2. News
    3. Search results
    Displaying results 1 - 25 of 668 Clear search
    Zyme Communications
    Dr Stephen Hoole, Consultant Cardiologist, Royal Papworth Hospital	Dr Simon Williams,  General Manager, PlaqueTec
    Healthcare and Life Science 12 Nov 2026

    PlaqueTec’s BIOPATTERN trial passes 100 patients and expands to 8 NHS centres

    PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to reveal the biological drivers of atherosclerotic cardiovascular disease (ASCVD), today announced that its BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist cardiac centre

    Zyme Communications
    Barton House, Abingdon Science Park
    Healthcare and Life Science 11 Nov 2026

    T-Cypher Bio extends footprint in purpose-built laboratory space at Abingdon Science Park, Oxford

    Newly built facility delivered by Kadans Science Partner at Barton House will support company growth and progression of novel T cell engager pipeline programmes

    Zyme Communications
    Dr. Jonathan Appleby Chief Scientific Officer, Mogrify  and Joe Foster Chief Executive Officer, Mogrify
    Healthcare and Life Science 11 Nov 2026

    Mogrify to present preclinical proof-of-concept data for first-in-class retinal in vivo reprogramming therapy

    Preclinical proof-of-concept data will be presented at the FLORetina-ICOOR 2026 Congress, taking place from 3 - 6 December 2026Data demonstrate that MOGRIFY-derived transcription factors can preserve and restore functional vision in a rodent model of photoreceptor degen
    Zyme Communications
    The Lab Thread Research Lab Management Software
    Healthcare and Life Science 10 Nov 2026

    Lab Thread launches new AI tools and strengthens platform with universal AI assistant compatibility

    · New MCP server connects external AI tools directly to structured laboratory data, with no exports or custom integrations required

    · Suite of AI functions address key data bottlenecks in biological research labs, from protocol writing to equipment set-up

    Zyme Communications
    Stuart Rose, CEO, BioUK Neil Roberts, MD, SEHTA
    Healthcare and Life Science 09 Nov 2026

    BioUK acquires certain key assets of SEHTA to strengthen support for life science SMEs across the UK

    Asset acquisition combines BioUK’s strength in biotech and therapeutics with SEHTA’s MedTech and HealthTech expertise, covering the full breadth of life science SMEsEnhances BioUK’s support offerings with SEHTA’s broad membership network and competencies in market acces
    Zyme Communications
    Edward Bruce-White, CEO, Combat Medical	Professor Joost Boormans, MD, PhD, Head of the Department of Urology, Erasmus MC
    Healthcare and Life Science 09 Nov 2026

    Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study

    Retrospective study evaluated the efficacy and safety of HIVEC® with mitomycin C in patients treated at the Erasmus Medical Center and Amphia hospital between 2015 and 2022Real-world data support HIVEC® as a bladder-preserving alternative to radica
    Zyme Communications
    Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics
    Healthcare and Life Science 09 Nov 2026

    Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

    Qureight’s Fibr8 model to provide structural assessment as secondary endpoint in Contineum’s Phase 2 PROPEL-IPF clinical trial examining the safety and efficacy of PIPE-791 in idiopathic pulmonary fibrosis (IPF) patientsAnnouncement comes after a recent European Respira
    Zyme Communications
    logo
    Healthcare and Life Science 05 Nov 2026

    Amphista Therapeutics to present AMX-883 data at American Society of Hematology (ASH) Annual Meeting

    AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia (AML)Additional abstract on AMX-883 BRAMLIE trial assessing safety, pharmacokinetics, and prel
    Zyme Communications
    QX Continuum™ and QX700™ ddPCR™ instrument family
    Healthcare and Life Science 03 Nov 2026

    Bio-Rad expands Precision Oncology Research Portfolio for Advanced Molecular Analysis Workflows

    Expanded Portfolio Includes New Droplet Digital™ PCR Assays, Reagents and Technologies to Support Oncology Research Applications and Extend the Capabilities of the QX700™ ddPCR™ Systems

    Zyme Communications
    Dr Simon Walsh, CSO, Qureight
    Healthcare and Life Science 02 Nov 2026

    Qureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials

    Peer-reviewed Viewpoint ‘Fibrosis extent on HRCT: the principal structural imaging biomarker for antifibrotic trials’ presents argument for measuring both lung function and fibrosis extent in antifibrotic trialsEvaluation of evidence from multiple studies positions fibr
    Zyme Communications
    Pluto Workstation
    Healthcare and Life Science 30 Oct 2026

    Curiox Biosystems strengthens commercial leadership to expand adoption of centrifuge-free sample preparation

    Curiox Biosystems Inc (Curiox), a provider of centrifuge-free (C-FREE™) sample preparation technologies for reproducible, automated flow cytometry workflows, today announced the expansion of its senior commercial team and the formation of a Strategic Advisory Board (SAB).

    Zyme Communications
    Atelerix logo
    Healthcare and Life Science, Science and Engineering 27 Oct 2026

    Atelerix and Frontier Space partner to enable biological sample preservation for space missions

    Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced a partnership with Frontier Space, a UK based space biotechnology company building platform technology for in-orbit R&D and biomanufact

    Zyme Communications
     Winners of the BioUK Awards 2026
    Healthcare and Life Science 22 Oct 2026

    BioUK Awards 2026 celebrate outstanding achievement and breakthrough innovations from across the Life Sciences

    Abingdon, UK - BioUK, the not-for-profit membership organisation focused on catalysing success in UK life sciences, announces the winners of the 18th annual BioUK Awards following a ceremony hosted at the Royal Lancaster Hotel, London.

    Zyme Communications
    Opening of BioLabs | TUM. From left to right: Dr. Johannes Fruehauf, CEO BioLabs, Dr. Max Pöhlmann, Site Director, BioLabs TUM, Dr. Floris Engelhardt, CEO/CSO & Co-Founder Kano Therapeutics, Dr. Philipp Gerbert, CEO TUM Venture Labs, Johanna Michielin, Regional Director, BioLabs Europe
    Healthcare and Life Science 21 Oct 2026

    Eppendorf and BioLabs expand collaboration to support biotech innovation in Munich

    •    The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies •    Builds on existing partnerships at BioLabs sites across the US, Germany and France

    Zyme Communications
    SPT Labtech’s firefly®+ 	Takara Bio’s SMART-Seq® mRNA LP
    Healthcare and Life Science 20 Oct 2026

    Takara Bio USA partners with SPT Labtech to deliver automation-ready NGS library preparation technologies

    Trusted NGS chemistries from Takara Bio now optimized for firefly® automated workflows

    Zyme Communications
     Dr. Adi Gilboa-Geffen, CEO of ScionxBio and  Dr. Yaniv Erlich, Chairman of the Board and co-founder of ScionxBio
    Healthcare and Life Science 20 Oct 2026

    ScionxBio announces collaboration to develop long-acting xRNA Therapeutics

    Cambridge, UK, 20 October 2026: ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd.

    Zyme Communications
    Simon Walsh, CSO, Qureight
    Healthcare and Life Science 20 Oct 2026

    Qureight appointed imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics expands

    Celea has now contracted Qureight as the end-to-end imaging CRO for the phase 3 SURPASS-IPF trial, including Fibr8™ and four additional AI imaging models Joint poster at CHEST 2026 presents analysis completed as part of Qureight’s work on Celea’s phase 2b ELEVATE-I
    Zyme Communications
    Leading Life Science Organisations Collaborate for Second London Bio-Innovation Week
    Healthcare and Life Science 14 Oct 2026

    Leading life science organisations collaborate for second London Bio-Innovation Week

    One Nucleus, SLAS, and ELRIG will connect their communities through cross-event networking and partnering opportunities during London Bio-Innovation Week
    Zyme Communications
    Dr. Yaniv Erlich, CEO and Co-Founder, Undecimal Bio, Shaul Ilan, COO and Co-Founder, Undecimal Bio
    Healthcare and Life Science 13 Oct 2026

    Undecimal Bio launches with $18 million oversubscribed Seed financing to address ‘liver trap’ in siRNA therapeutic delivery

    ·  A spin-out focused on AI-enabled decoding of the deliverome

    ·  Proprietary synthetic biology platform identifies conjugates that target RNA medicines beyond the liver, with initial focus on renovascular disease

    Zyme Communications
    Pierre Arsène, Founder and CEO, Mursla Bio	Dr Tomás Dias, CSO, Mursla Bio
    Healthcare and Life Science 13 Oct 2026

    Mursla Bio publishes peer-reviewed validation of Tissue-Specific Extracellular Vesicle Platform for Liquid Biopsy

    Study published in Journal of Extracellular Vesicles validates platform for new class of liquid biopsy: multiomic disease biology of living cells from a chosen tissue, starting with the liver Platform underpins FDA Breakthrough Device-designated EvoLiver™ and preci
    Zyme Communications
    ‘Lab-in-the-loop’ workflow
    Healthcare and Life Science 12 Oct 2026

    Google DeepMind’s Nature Study on Watermarking AI-Designed Proteins Validated with Carterra HT-SPR

    New paper published in Nature shows watermarks can be embedded in AI-generated proteins without compromising function, confirmed with binding kinetics data from Carterra’s LSA-XT

    Zyme Communications
    Dr Louise Modis, Chief Executive Officer, Amphista	Dr Eytan Stein, Director, Program for Drug Development in Leukemia, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center
    Healthcare and Life Science 12 Oct 2026

    Amphista Therapeutics announces first patient dosed in AMX-883 Phase 1 clinical trial for acute myeloid leukemia

    AMX-883, Amphista’s first asset to enter the clinic, is a potent, selective, orally bioavailable DCAF16-mediated BRD9 degrader targeting acute myeloid leukemia (AML) The first-in-human ‘BRAMLIE’ (BR(D9) AML Interventional Evaluation) trial will assess the safety, p
    Zyme Communications
    Carterra logo
    Healthcare and Life Science 07 Oct 2026

    Carterra advances lab-in-the-loop drug discovery through new scientific collaboration

    Bringing together scientific and technical expertise to advance development of hardware and software aimed at enabling a new wave of AI-driven, autonomous biologics discovery

    Zyme Communications
    Prashant Shah, Co-founder, o2h Group
    Healthcare and Life Science 05 Oct 2026

    Cambridge and London Life Sciences Showcase returns during JPM Healthcare Week 2027

    · o2h co-discovery to host second edition of the Cambridge x London Life Sciences Showcase, taking place on 13 January 2027 at 111 Minna Gallery, San Francisco 

    Zyme Communications
    Dr Brendan Swain, CSO and Founder, Shift Bioscience
    Healthcare and Life Science 05 Oct 2026

    Shift Bioscience publication increases confidence in AI virtual cells for novel target discovery

    · Nature Biotechnology publication details improved calibration framework for deep learning-based genetic perturbation models

    Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • …
    • Next page ›
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS